New Markers for Treatment Response to Radiotherapy in Prostate Cancer

Withdrawn

• Conditions: Prostate Cancer

• Registration Number: NCT06159998
• Lead Sponsor: University of Basel

Brief Summary

The actual follow-up of patients undergoing definite radiotherapy for prostate cancer includes regular measurements of prostate specific antigen (PSA). Successful radiotherapy is critically dependent on local control of cancer; however, PSA takes 2-3 years to reach a nadir after therapy. We aim at collecting blood/urine after prostate massage before, and after radiotherapy in order to define new markers predicting local control earlier and more precisely than PSA.

Detailed Description

Patients will be closely followed for 5 years (weeks 0, 2, 4, 6, and months 2, 3, 6, 9, 12, 18, 24, and then yearly). Each assessment includes PSA measurement, urine collection after prostatic massage, and blood collection.

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2012-12-11
• Primary Completion: 2014-07
• Study Completion: 2019-07
• Status Verified: 2023-11
• Study First Submitted QC: 2023-11-28
• Last Update Submitted: 2023-11-28
• Study First Posted: 2023-12-07
• Last Update Posted: 2023-12-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

• All patients undergoing radiotherapy of biopsy confirmed clinically localised adenocarcinoma of the prostate

Exclusion Criteria

• patients with inflammatory processes of the rectum
• patients with no rectum due to previous surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bio-repository	first assessment using predifined markers after recruitment of 15 patients followed for 1 year

Trial Locations

Locations (1)

Department of Urology, University Hospital Basel; 🇨🇭 Basel, Basel-Stadt, Switzerland